Meeting
2014 Gastrointestinal Cancers Symposium
Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Authors
Ghassan K. Abou-Alfa
Memorial Sloan-Kettering Cancer Center, New York, NY
Ghassan K. Abou-Alfa , Jean-Frédéric Blanc , Steven Miles , Tom M. Ganten , Jorg Trojan , Jonathan S. Cebon , Andre K. D. Liem , Lara Rachel Lipton , Charu Gupta , Benjamin Wu , Jason B. Litten , Leonard Saltz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00872014
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 286)
DOI
10.1200/jco.2014.32.3_suppl.286
Abstract #
286
Poster Bd #
C1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel
Poster
2018 Gastrointestinal Cancers Symposium
A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).
First Author: Lipika Goyal
Poster
2015 Gastrointestinal Cancers Symposium
Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
First Author: Ann-Lii Cheng
Poster
2015 Gastrointestinal Cancers Symposium
A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).
First Author: Adam Charles Yopp